STOCK TITAN
  1. Home
  2. News
  3. THTX

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

News
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Rhea-AI Summary
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) receives FDA approval for updated label allowing for easier and more convenient administration of Trogarzo® for heavily treatment-experienced adults with HIV. The label update includes a 2000-mg intravenous (IV) push loading dose, reducing administration time to 90 seconds for the loading dose and 30 seconds for a maintenance dose every two weeks. This approval further simplifies the administration of Trogarzo® for heavily treated people with HIV, enhancing the convenience of non-oral therapy for this important group of people.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
fda approval
-
News
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Rhea-AI Summary
Theratechnologies Inc. (TH) receives the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award for advancing preclinical development of sudocetaxel zendusortide for the treatment of triple-negative breast cancer. The award recognizes the company's partnership with Professor Borhane Annabi of UQAM and the successful preclinical efficacy of its investigational peptide-drug conjugate TH1902. Sudocetaxel zendusortide has received Fast Track designation from the FDA and is currently in a Phase 1 clinical trial in the U.S. and Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
-
News
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Rhea-AI Summary
Theratechnologies Inc. has closed its previously announced public offering, raising gross proceeds of US$12.5 million. The offering consisted of 12.5 million common shares at a price of US$1.00 per share. The underwriter has been granted a 30-day option to purchase an additional 1.875 million common shares. The company also closed a concurrent private placement with Investissement Québec, resulting in aggregate gross proceeds of US$12.5 million. Investissement Québec now beneficially owns approximately 19.9% of the issued and outstanding common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
offering
News
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Rhea-AI Summary
Theratechnologies Inc. has priced its public offering of 12,500,000 common shares at a price of US$1.00 per share, with expected gross proceeds of approximately US$12,500,000. The company has also granted the underwriter a 30-day option to purchase up to 1,875,000 common shares at the offering price. A concurrent private placement with Investissement Québec for 9,118,184 common shares and exchangeable subscription receipts is also part of the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.13%
Tags
offering
-
News
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Rhea-AI Summary
Theratechnologies Inc. has announced the launch of a marketed public offering of common shares, as well as a concurrent private placement with Investissement Québec. The underwriter has been granted an option to purchase additional shares. The consummation of the private placement is contingent upon the closing of the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.13%
Tags
offering
-
News
Theratechnologies Announces Operational Update
Rhea-AI Summary
Theratechnologies Inc. announces changes to its operations, including a reduction of up to 25 positions. The company expects to save approximately US$3.5 million per year and record a restructuring charge of approximately US$1.5 million in Q4 2023. Clinical research activities in oncology and NASH will be made through partnership deals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags
none
News
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Rhea-AI Summary
Theratechnologies shares data on the cost-effectiveness of ibalizumab for heavily treatment-experienced people with HIV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
News
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Rhea-AI Summary
Theratechnologies presents data demonstrating that treatment with tesamorelin reduces visceral adipose tissue (VAT) and hepatic fat fraction (HFF) in people with HIV on integrase inhibitor-based regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
News
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
Rhea-AI Summary
Theratechnologies announces results from TMB-302 study on Trogarzo® administration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
News
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Rhea-AI Summary
Theratechnologies announces dosing of the first participant in Phase 1 clinical trial of sudocetaxel zendusortide in ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
clinical trial
Stock THTX logo
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

#4595 Ranked by Market Cap
#5441 Ranked by Stock Gains
N/A Ranked by Dividends

THTX Stock Data

65.29M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.